HIGHLIGHTS
- who: Simke W. Waijer from the (UNIVERSITY) have published the Article: Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial, in the Journal: (JOURNAL) of 30/01/2017
- what: For the purpose of the current analysis, the authors evaluated the primary and secondary efficacy endpoints in patients stratified by the modified KDIGO risk categories. The authors demonstrated that, in patients without type 2 diabetes, the effect of dapagliflozin on kidney and cardiovascular outcomes is consistent across KDIGO risk categories and the spectrum . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.